Vebreltinib for Advanced or Metastatic CCS

Summary

This is a prospective, cohort, multicenter study. Cohort 1 is treatment group. All eligible subjects will receive Vebreltinib (200 mg bid po) after signing the informed consent and meeting the inclusion/exclusion criteria, until disease progression, intolerable toxicity, or death. Subjects will undergo MET abnormality testing after enrollment, including MET amplification or MET protein overexpression. Cohort 2 is external reference group. Subjects diagnosed with CCS and met the inclusion criteria but refused to enter Cohort1 will receive the standard treatment decided by investigators. These subjects will receive follow-up. The efficacy and safety data will be collected. Imaging evaluation will be performed using RECIST v1.1, with CT or MR plain scans every two months (±7 days) until disease recurrence or death. During the study, subjects will receive safety follow-up, and survival follow-up will be conducted every two months after treatment, which can be done by telephone interview for approximately 3 years after treatment ends.

Timeline

Start

2025-09-30

Primary completion

2026-07-15

Completion

2027-07-15

Publications

• Jiang Y, Lin N, Huang X, Yan X, Liu M, Qu H, Li X, Lin P, Li H, Ye Z, Li B. VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma. Future Oncol. 2026 Jun 30:1-7. doi: 10.1080/14796694.2026.2695212. Online ahead of print.

Drugs

Indications